Abstract
In this chapter, we describe how to determine the kill kinetics and minimum bactericidal concentration (MBC) of a compound against Mycobacterium tuberculosis. Techniques are described for three conditions: actively growing aerobic bacteria, and non-replicating bacteria induced by nutrient starvation and/or low pH. Each technique involves determining the number of viable bacteria in the presence of several concentrations of compound over 3 weeks. Guidelines for how to interpret the results, to determine if growth-inhibitory compounds are bactericidal or bacteriostatic and also whether compounds exhibit time-dependent or concentration-dependent kill are provided.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
NCCLS (1999) Methods for determining bactericidal activity of antimicrobial agents; approved guideline. NCCLS document M26-A
Herbert D, Paramasivan CN, Venkatesan P et al (1996) Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother 40(10):2296–2299
Paramasivan CN, Sulochana S, Kubendiran G et al (2005) Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother 49(2):627–631
French GL (2006) Bactericidal agents in the treatment of MRSA infections – the potential role of daptomycin. J Antimicrob Chemother 58(6):1107–1117
Vaddady PV, Lee RE, Meibohm B (2010) In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB. Future Med Chem 2(8):1355–1369
Golan D, Tashjian AH Jr, Armstrong EJ et al (2012) Principles of pharmacology: the pathophysiologic basis of drug therapy, 3rd edn. Lippincott Williams & Wilkins, Philadelphia
Opie EL, Aronson JD (1927) Tubercule bacilli in latent tuberculous lesions and in lung tissue without tuberculosis. Arch Pathol Lab Med 4:1–21
Dickinson JM, Mitchison DA (1981) Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. Am Rev Respir Dis 4:367–371
Zhanel GG, Kirkpatrick IDC, Hoban DJ et al (1998) Influence of human serum on pharmacodynamic properties of an investigational glycopeptide, LY333328, and Comparator agents against Staphylococcus aureus. Antimicrob Agents Chemother 42(9):2427–2430
Rakesh, Bruhn DF, Scherman MS et al (2014) Pentacyclic nitrofurans with in vivo efficacy and activity against nonreplicating Mycobacterium tuberculosis. PLoS One. doi:10.1371/journal.pone.0087909
England K, Boshoff HIM, Arora K et al (2012) Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother 56:3384–3387
Andreu N, Fletcher T, Krishnan N et al (2012) Rapid measurement of antituberculosis drug activity in vitro and in macrophages using bioluminescence. J Antimicrob Chemother 67:404–414
Wayne LG (1994) Cultivation of Mycobacterium tuberculosis for research purposes. In: Bloom BR (ed) Tuberculosis: pathogenesis, protection, and control. American Society for Microbiology Press, Washington, DC, pp 73–83
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this protocol
Cite this protocol
Early, J., Alling, T. (2015). Determination of Compound Kill Kinetics Against Mycobacterium tuberculosis . In: Parish, T., Roberts, D. (eds) Mycobacteria Protocols. Methods in Molecular Biology, vol 1285. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2450-9_16
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2450-9_16
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-2449-3
Online ISBN: 978-1-4939-2450-9
eBook Packages: Springer Protocols